Combination Therapy Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Associated with Hepatic Failure

Title:Combination Therapy Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Associated with Hepatic Failure

Volume: 7 Issue: 5

Author(s): Sohail Qayyum, Huijun Dong, Dianne Kovacic, Sidra Sohail, Bradford Waters, Camille Thornton and Cathy E. Corbett

Affiliation:

Keywords: Drug induced hepatic failure, AIDS combination therapy, antiretroviral, NNRTI, Emtricitabine, hepatic failure, hepatotoxicity, gonococcal, syphilis, genital herpes

Abstract: A single pill daily fixed dose combination of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) provides a potent and convenient treatment option for HIV/AIDS. The components have been shown to be well tolerated and are effective in randomized controlled trials. A literature search revealed no case of hepatic failure reported with this drug combination. We here in describe the 1st case of acute hepatic failure developing after 3 months of treatment with EFV/FTC/TDF in a 41 year old African American male without pre-existing liver disease or risk factors.

Cite this article as:

Qayyum Sohail, Dong Huijun, Kovacic Dianne, Sohail Sidra, Waters Bradford, Thornton Camille and E. Corbett Cathy, Combination Therapy Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Associated with Hepatic Failure, Current Drug Safety 2012; 7 (5) . https://dx.doi.org/10.2174/1574886311207050013